Search

Displaying results 1191 - 1200 of 4238 in total
  1. Drug

    Guanidine

    go.drugbank.com/drugs/DB00536
    Approved

    A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. … It is also used in laboratory research as a protein denaturant.

  2. Drug

    Limaprost

    go.drugbank.com/drugs/DB09211
    Investigational

    Limaprost (as Limaprost alfadex; CAS number 88852-12-4) is an oral prostaglandin E1 analog. … It was approved for the treatment of ischemic symptoms such as skin ulcer, pain and coldness accompanying thromboangiitis obliterans in 1988; and for the treatment of subjective symptoms such as pain and

  3. Drug

    Estradiol dienanthate

    go.drugbank.com/drugs/DB13955
    ApprovedVet approvedWithdrawn

    Esterification of estradiol aims to improves absorption and bioavailability after oral administration (such as with Estradiol valerate) or to sustain release from depot intramuscular injections (such as … Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone.

  4. Indication

    Necrotizing ulcerative gingivostomatitis

    go.drugbank.com/conditions/DBCOND0025061
    Drugs: Demeclocycline · Procaine benzylpenicillin · Tetracycline
    Synonyms: AUG - Acute ulcerative gingivitis
  5. Drug

    Calcium threonate

    go.drugbank.com/drugs/DB11168
    ApprovedWithdrawn

    It is found in dietary supplements as a source of L-threonate used in the treatment of calcium deficiency and prevention of osteoporosis. … Calcium threonate is a calcium salt of threnoic acid and a novel drug developed for the treatment of osteoporosis and as a calcium supplement [A27266].

  6. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    [A20301] When used in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding … Lumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older.

  7. Drug

    Temafloxacin

    go.drugbank.com/drugs/DB01405
    ApprovedWithdrawn

    It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three

  8. Drug

    Ondansetron

    go.drugbank.com/drugs/DB00904
    ApprovedInvestigationalWithdrawn

    Commonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as generic products as well, ondansetron continues to see contemporary innovations in its formulation … Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy.

    Products: Ondansetron Tenshi Kaizen 4 mg Schmelztabletten, Ondansetron Tenshi Kaizen 8 mg Schmelztabletten
  9. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021.

  10. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    [L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia. … [T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture.